Physician profile
Salman Fidahussein
NPI 1225298029
$852,309.11
in general payments reported to CMS, 2019-2025
31 companies · $167K in 2025
The $167K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $25K · 2021: $82K · 2022: $145K · 2023: $163K · 2024: $174K · 2025: $167K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $435K · Travel and Lodging: $44K · Food and Beverage: $12K · Consulting Fee: $11K · Education: $2,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $434,600.00 |
| Travel and Lodging | $44,142.63 |
| Food and Beverage | $12,154.89 |
| Consulting Fee | $10,946.25 |
| Education | $2,508.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $710,192.35 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67,629.74 | 2019-2025 | Ofev |
| Sunovion Pharmaceuticals INC. | $23,166.64 | 2019-2021 | |
| Genentech USA, INC. | $16,956.33 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $10,684.34 | 2019 | |
| Mylan Specialty L.P. | $8,961.06 | 2019-2022 | |
| Allergan, INC. | $7,177.40 | 2019-2020 | |
| Intuitive Surgical, INC. | $3,689.84 | 2022-2025 | Da Vinci Sp |
| Mallinckrodt Hospital Products INC. | $2,150.00 | 2020 | |
| Glaxosmithkline, LLC. | $588.25 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Insmed, INC. | $252.68 | 2019-2025 | Brinsupri, Arikayce |
| Pulmonx Corporation | $105.45 | 2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Medtronic, INC. | $87.72 | 2023 | Illumisite |
| Becton, Dickinson and Company | $85.37 | 2023-2025 | Hemosphere |
| Astellas Pharma US INC | $74.99 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70.46 | 2019-2020 | |
| Genzyme Corporation | $57.15 | 2020-2025 | |
| Csl Behring | $57.13 | 2019 | |
| Janssen Biotech, INC. | $45.19 | 2019-2022 | |
| Scpharmaceuticals INC. | $43.08 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.09 | 2019-2020 | |
| Amgen INC. | $33.15 | 2024-2025 | Tezspire |
| Stryker Corporation | $31.16 | 2025 | Sage Self Oral Care |
| Ani Pharmaceuticals, INC. | $22.63 | 2024 | Purified Cortrophin Gel |
| Phadia US INC. | $17.87 | 2019 | |
| Shire North American Group INC | $17.59 | 2019 | |
| United Therapeutics Corporation | $17.03 | 2019-2021 | |
| Resmed Corp | $15.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.97 | 2025 | Glassia |
| Veran Medical Technologies, INC. | $14.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Fidahussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.